Acarix AB (publ) (ACIXF)

Acarix AB (publ) (ACIXF) Healthcare & Pipeline Overview

Acarix AB (publ) is a Swedish medical device company developing AI-powered point-of-care diagnostics for rapid coronary artery disease (CAD) rule-out. Its CADScor System leverages sensitive acoustics and advanced AI to analyze coronary blood flow, positioning the company within the evolving cardiology diagnostics market.

What Is the Investment Thesis for ACIXF?

Acarix AB (publ) presents an investment thesis centered on its innovative CADScor System, an AI-based point-of-care diagnostic for coronary artery disease (CAD) rule-out. The system’s utilization of sensitive acoustics and advanced AI positions it as a potentially disruptive technology in a large and critical addressable market within cardiology. Key value drivers include the potential for widespread adoption due to its non-invasive, rapid, and AI-powered diagnostic capabilities, which could improve patient pathways and reduce healthcare costs. Growth catalysts are anticipated from increasing commercial traction of the CADScor System, potential geographic expansion beyond Sweden, and securing further funding to support product development and market penetration. However, the company operates with a negative profit margin of -530.9% and a relatively small market capitalization of $31.28M, indicating it is in an early commercialization or growth phase. As an OTC Other listed stock, ACIXF carries inherent liquidity risks and requires close monitoring of its ability to achieve sustainable commercial success and secure necessary capital for ongoing operations and expansion.

Based on FMP financials and quantitative analysis

ACIXF Key Highlights

• Market capitalization stands at $0.03 billion, reflecting a relatively small-cap company in the medical device sector.
• The company reported a gross margin of 65.6%, indicating strong profitability on its core product sales before operating expenses.
• Acarix AB (publ) currently operates with a significant negative profit margin of -530.9%, underscoring its early-stage commercialization or investment phase.
• A Beta of -0.24 suggests the stock has historically moved inversely to the broader market, though this can be less reliable for small, illiquid stocks.
• The company does not currently offer a dividend yield, consistent with a growth-oriented medical device firm reinvesting earnings.

Who Are ACIXF's Competitors?

ACIXF is benchmarked below against 6 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ACIXF's Key Strengths?

• Innovative AI-based CADScor System for rapid CAD rule-out.
• Proprietary technology combining sensitive acoustics and advanced AI.
• Addresses a large and critical addressable market in cardiology diagnostics.
• Point-of-care diagnostic aid offers convenience and efficiency.

What Are ACIXF's Weaknesses?

• Small market capitalization ($0.03B) and limited employee base (8 employees).
• Significant negative profit margin (-530.9%) indicates unprofitability.
• Reliance on a single primary product, the CADScor System.
• Exposure to liquidity risks as an OTC Other listed stock.

What Could Drive ACIXF Stock Higher?

• Successful achievement of commercial traction for the CADScor System in key markets, demonstrating increasing sales volumes and adoption rates.
• Securing additional funding rounds or strategic partnerships to support ongoing operations, research and development, and market expansion initiatives.
• Positive results from ongoing or future clinical studies further validating the efficacy and cost-effectiveness of the CADScor System.
• Expansion of the CADScor System's market reach into new international territories through regulatory approvals and distribution agreements.

What Are the Key Risks for ACIXF?

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Significant negative profit margin (-530.9%) indicates persistent unprofitability and a high cash burn rate, necessitating continuous funding.
• Inherent liquidity risks associated with being an OTC Other listed stock, potentially hindering investor's ability to trade shares efficiently.
• Failure to achieve sufficient commercial traction and widespread adoption of the CADScor System in a competitive medical device market.
• Challenges in securing adequate future funding to sustain operations, research, and development, and market expansion.
• Exposure to regulatory changes and the complex process of obtaining and maintaining medical device approvals in various jurisdictions.

What Are the Growth Opportunities for ACIXF?

• Market Penetration and Adoption of CADScor System: Acarix's primary growth opportunity lies in increasing the adoption and market penetration of its CADScor System. The global market for cardiovascular disease diagnostics is substantial, driven by an aging population and rising incidence of heart conditions. By effectively demonstrating the clinical utility and cost-effectiveness of its rapid, AI-based rule-out system, Acarix can expand its footprint in existing markets like Sweden and enter new international territories. Successful clinical outcomes and positive healthcare provider feedback will be crucial in accelerating this adoption, potentially tapping into a multi-billion dollar diagnostic market over the next 3-5 years.
• Geographic Expansion into Key International Markets: While currently operating in Sweden and internationally, a focused strategy for expanding into major healthcare markets, such as the European Union, North America, or parts of Asia, represents a significant growth avenue. Each new market entry requires navigating distinct regulatory landscapes, reimbursement policies, and healthcare system structures. Successfully establishing distribution channels and securing regulatory approvals in these regions could unlock substantial revenue streams, potentially doubling or tripling the addressable market for the CADScor System within a 3-7 year timeframe.
• Further Technological Advancement and AI Algorithm Enhancement: Continuous investment in research and development to enhance the CADScor System's AI algorithms and acoustic sensing capabilities could improve diagnostic accuracy, expand its utility, or reduce operational costs. This could involve refining the AI for broader patient populations, integrating with other diagnostic data, or developing next-generation hardware. Such advancements would strengthen the product's competitive advantage and could lead to new intellectual property, ensuring the system remains at the forefront of non-invasive CAD diagnostics for the next 5-10 years.
• Strategic Partnerships and Distribution Agreements: For a company with 8 employees and a relatively small market capitalization, forming strategic partnerships with larger medical device companies or established healthcare distributors could significantly accelerate market access and commercial scale. These collaborations could provide access to broader sales networks, established customer bases, and greater resources for marketing and support. Such alliances could rapidly expand the system's reach and adoption, potentially impacting revenue growth within the next 2-4 years.
• Securing Favorable Reimbursement and Clinical Guidelines Inclusion: The long-term success and widespread adoption of the CADScor System depend heavily on securing favorable reimbursement codes and achieving inclusion in clinical practice guidelines. Demonstrating strong health economic outcomes and robust clinical evidence is critical for this. Successful efforts in this area would remove financial barriers for healthcare providers and integrate the system into standard diagnostic protocols, significantly expanding its addressable market and driving consistent revenue growth over the next 5-8 years.

What Opportunities Does ACIXF Have?

• Expansion into new international markets for the CADScor System.
• Further development and enhancement of AI algorithms and acoustic technology.
• Strategic partnerships to accelerate market access and distribution.
• Potential for new applications or indications for the core technology.

What Threats Does ACIXF Face?

• Intense competition from established medical device companies and new entrants.
• Challenges in securing widespread clinical adoption and favorable reimbursement.
• Regulatory hurdles and evolving standards for medical device approval.
• Need for continuous funding to support operations and commercialization efforts.

What Are ACIXF's Competitive Advantages?

• Proprietary AI-based diagnostic algorithms for coronary blood flow analysis.
• Unique application of sensitive acoustics for non-invasive CAD detection.
• Point-of-care functionality offering rapid results, potentially streamlining diagnostic pathways.
• Early mover advantage in combining these specific technologies for CAD rule-out.
• Regulatory approvals and clinical validation for the CADScor System.

What Does ACIXF Do?

Acarix AB (publ), founded in 2009 and headquartered in Malmö, Sweden, operates as a medical device company dedicated to advancing diagnostic solutions for coronary artery disease (CAD). The company's core innovation is the CADScor System, a proprietary point-of-care diagnostic aid designed for the rapid rule-out of CAD in both Swedish and international markets. This system represents a significant technological advancement by integrating sensitive acoustic detection with sophisticated artificial intelligence algorithms. The CADScor System functions by analyzing a patient's coronary blood flow, providing healthcare professionals with a non-invasive tool to assess the risk of CAD. Its development addresses a critical need for efficient and accurate early detection methods, aiming to streamline diagnostic pathways and potentially reduce the burden on more invasive procedures. The company's focus on AI-based diagnostics places it at the forefront of leveraging emerging technologies to improve patient outcomes in cardiology. With its headquarters in Sweden, Acarix AB (publ) is strategically positioned to serve European markets while also pursuing global expansion. The company's evolution since its founding reflects a commitment to innovation in medical diagnostics, specifically targeting a large addressable market within cardiovascular health.

What Products and Services Does ACIXF Offer?

• Develops medical devices for rapid rule-out of coronary artery disease (CAD).
• Offers the CADScor System, a point-of-care diagnostic aid.
• Utilizes sensitive acoustics to analyze patient's coronary blood flow.
• Employs advanced Artificial Intelligence (AI) for diagnostic analysis.
• Aims to identify patients with a high risk of coronary artery disease.
• Operates in Sweden and across international markets.
• Focuses on non-invasive diagnostic solutions in cardiology.

How Does ACIXF Make Money?

• Generates revenue through the sale of its CADScor System, a medical diagnostic device.
• Potentially earns revenue from associated consumables, service contracts, or software licenses for the AI component.
• Targets healthcare providers, hospitals, and clinics as primary customers for its diagnostic technology.
• Relies on commercialization efforts and market adoption of its proprietary technology.

What Industry Does ACIXF Operate In?

Acarix AB (publ) operates within the Medical - Specialties industry, specifically targeting the cardiology diagnostics market. This sector is characterized by continuous innovation, driven by the increasing prevalence of cardiovascular diseases globally and the demand for more efficient, non-invasive diagnostic tools. The market for coronary artery disease diagnostics is substantial, with a growing emphasis on early detection and risk stratification. Acarix's CADScor System, leveraging AI and acoustics for rapid rule-out, positions the company within the emerging trend of AI-powered diagnostics. The competitive landscape includes established medical device companies offering traditional diagnostic methods (e.g., ECG, stress tests, imaging) as well as other innovators exploring novel biomarkers or imaging techniques. Acarix differentiates itself through its point-of-care, AI-driven approach, aiming to provide a quicker and less resource-intensive initial assessment compared to more complex or time-consuming diagnostic pathways.

Who Are ACIXF's Key Customers?

• Cardiology departments in hospitals and clinics.
• General practitioners and primary care physicians seeking early CAD rule-out tools.
• Emergency departments requiring rapid assessment of chest pain patients.
• Healthcare systems and integrated delivery networks focused on improving diagnostic pathways.

Acarix AB (publ) Financial Trajectory

Acarix AB (publ) (ACIXF) reported $2.4M in revenue for Q1 2026, reflecting 13.1% growth compared to the prior quarter. The company recorded a net loss of $8.8M, with diluted EPS of $-0.01. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, ACIXF averaged $-0.01 in diluted EPS.

Company Profile

Acarix AB (publ) operates in the Medical - Specialties industry within the Healthcare sector. It is headquartered in Malmö, SE. The company is led by CEO Aamir Mahmood. ACIXF has traded publicly since 2022.

How Acarix AB (publ) Is Valued

Acarix AB (publ) carries a market capitalization of $31.28M, placing it in the micro-cap category. Relative to its peer group, ACIXF's quantitative score of 52/100 is roughly in line with the peer average of 49/100.

Key Financial Metrics

Return on assets is -98.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -13.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.72 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -14.4%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 2/9Financial Health

Acarix AB (publ)'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 5.08 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Acarix AB (publ) revenue of about $19.0M for fiscal 2026, with EPS near $0.11.

ACIXF Financials

ACIXF Latest News

ACIXF Analyst Consensus

ACIXF MoonshotScore

What Investors Ask About Acarix AB (publ) (ACIXF) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources